Americans are optimistic, which is a positive trait. As lawmakers navigate what is expected to be the last bankruptcy of the Covid-19 pandemic, there is an explanation for why they are optimistic. The country now has a difficult tool, vaccines, to run it. in the right direction After an uneven launch, the vaccination rate increases over time.
The country’s optimism is also fueled by the fact that Covid-19 signals have advanced nationally for consecutive weeks.
But in response, most state pastors, who in the US federalist formula, are not able to do so. But it’s not the first time In the end, they are making the most of Covid-19’s mitigation policy, they are declining cautiously. Some gradually loosen the reins, turning capacity limits, for example, into domestic enterprises; others, however, go much further by completely getting rid of limits on indoor capacity, even when it comes to event venues (sports) and meals, and cutting masks.
Clearly, while the United States is in open mode, in some states at full speed, most of Europe continues to implement strict mitigation measures, firmly resisting the concept that the time has come to abandon.
The United States and Europe face a similar set of problems. They are still dealing with a primary pandemic, the desire to vaccinate as well as imaginable and the wonderful unknown of potentially harmful variants that can complicate things.
However, policies to counteract the spread of coronavirus are, for all purposes, diametrically opposed at this stage. State governors seem to think that, according to top public aptitude experts, this is not the right time to ease Covid-19 restrictions. on the contrary, a simultaneous dual strategy of strong mitigation and immediate vaccination is more appropriate.
Despite the improvement in Covid-19 indicators, the challenge of lack of mitigation is highlighted by the fact that cases, hospitalizations and deaths are still at higher levels than past peaks.
And if it is too early to be definitive, it turns out that possibly an uptick in the instances of Covid-19 would be positioned in the Great Plains. What is troubling about the news is that it is the dominance that triggered the recent peak and along the country’s deadliest wave.
Vaccines and herbal immunity acquired from beyond infections are likely to result in a primary national resurgence of cases, hospitalizations and deaths this time, but caution is required, in the event of new variants, reluctance to vaccinate, especially among some. vulnerable maximum subpopulations – and the prospect of reinfection when immunity decreases or as a result of mutations in the new coronavirus. It is one thing to defend against the B. 1. 1. 7 outbreak, to treat other, more worrying variants, opposite to which vaccines would possibly be less protective, is a totally different ball game. This includes variants P. 1 and 501Y. V2.
Across Europe, variant B. 1. 1. 7 is fitting dominant. Despite a sharp drop in the number of cases in January in peak European countries due to strict closures, the hospitalization curve (and extensive care use) has not declined as much Of course, there is a gap between declining new daily cases and relief in hospitalizations, but the fall in hospitalizations has been less than the decrease in cases for more than six weeks , we don’t know why. Perhaps this is because of the greater severity of B. 1. 1. 7.
The Netherlands scenario is a good example. After a steady decline in new daily instances in January, hospitalizations (and intensive care use) decreased, but not so much. In addition, this month we see a limit on the 3 signs in the Netherlands. In addition, the plateau is not even close to the lowest point at the end of spring 2020. In fact, for the 3 Covid-19 signs, it is 20 to 30 times taller.
The figures below come from the Dutch equivalent of the Centers for Disease Control and Prevention (CDC), the RIVM. The first graphic shows the new daily instances from November 1, 2020 to the day provided. a minimum about 10 days ago after a 65% decrease, and lately it’s expanding slightly. The graph at the moment shows that after a minimum of 30% in January and early February, hospitalizations and the use of extensive care are now stable. how daily deaths, after falling in January to around 38%, have stagnated in recent weeks.
Based on recent highs, Prime Minister Rutte announced thursday (February 18) that strict restrictions on Covid-19 were unlikely to be lifted in early March. Prime Minister Boris Johnson has also doubted the UK’s mitigation measures. .
Note that when the first Covid-19 pandemic occurred, Rutte and Johnson were among the top opposites to competitive action. Both leaders were even attracted to the concept of collective immunity. What a difference a year ago makes.
To finish the pandemic as best as possible, vaccination and mitigation will need to continue at the same time, but this two-point strategy does not occur in many parts of the United States, as many states rely almost exclusively on vaccines to get the job done. work And it’s not a political issue. The red and blue states are likely to be in favor of vaccines now, there is much less desire to mitigate them. Given the uncertainty surrounding the pandemic path in the short term, US lawmakers might want to take a look at Europe in search of classes on how to take a more cautious and cautious approach.
I am an independent fitness analyst with over 22 years of experience in fitness care and pharmaceutical analysis. Specifically, I analyze the price (costs and benefits) of
I am an independent fitness analyst with over 22 years of experience in fitness care and pharmaceutical analysis. Specifically, I analyze the price (costs and benefits) of biological and pharmaceutical products, patients’ access to prescription drugs, regulatory frameworks for drug progression, and reimbursement. , and ethics in the distribution of fitness resources. I have more than 110 publications in industry journals and peer-reviewed journals, as well as newspapers and periodicals. I have also presented my paintings at industrial, commercial and educational congresses. From 1999 to 2017, he was an associate professor of studies at the Tufts Center for the Study of Drug Development. Prior to my appointment at Tufts, I was a postdoctoral fellow at the University of Pennsylvania and finished my PhD in economics at the University of Amsterdam. PhD, I was a control representative at Accenture in The Hague, Netherlands. Currently, I work as a freelancer in a variety of studies, including teaching and writing projects.